Pre-made Landogrozumab benchmark antibody ( Whole mAb, anti-MSTN/GDF-8 therapeutic antibody, Anti-GDF8/MSLHP Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Landogrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.
| Products Name (INN Index) | Pre-Made Landogrozumab biosimilar, Whole mAb, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody |
|---|---|
| INN Name | Landogrozumab |
| Target | MSTN |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Eli Lilly |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Cancer,Cachexia,Muscular atrophy,Pancreatic cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MSTN |
| Package |
